CurifyLabs Launches 3D-Printed Veterinary Medicine Platform to Address Pet Medication Compliance Challenges
核心洞察
CurifyLabs (搜索) has launched Curablend Vet (搜索), a new veterinary excipient system that enables 3D-printed, palatable, and personalized medicines for pets to address dosage-specific medicine shortages in veterinary care.
The platform creates flavored, chewable gel tablets designed to look and feel like treats, with clinical data showing voluntary consumption by a large majority of 31 dogs and 38 cats tested.
The standardized, automated 3D-printing workflow replaces labor-intensive manual compounding methods and brings the same quality-controlled technology already used in human medicine to veterinary applications.
CurifyLabs (搜索) has announced the launch of Curablend Vet (搜索), a veterinary excipient system that leverages 3D printing technology to create personalized, palatable medicines for pets. The platform addresses critical gaps in veterinary pharmaceutical care by providing standardized, automated solutions for drug compounding that have previously been limited to human medicine applications.
Addressing Veterinary Compounding Challenges
The new system responds to a significant problem in veterinary care: the frequent lack of dosage-specific medicines for animals. This shortage typically forces pharmacists to manually manipulate human drug products or prepare ad-hoc formulations, processes that can be labor-intensive and introduce variability in medication quality and consistency.
Built for use with the CurifyLabs (搜索) Compounding System Solution (搜索) (CSS), Curablend Vet (搜索) brings what the company describes as "a new level of quality, safety, and predictability" to veterinary drug compounding through its standardized, automated, and digitally documented 3D-printing workflow.
Clinical Evidence for Pet Acceptance
A key innovation of the Curablend Vet (搜索) system is its approach to medication palatability. The platform produces flavored, chewable gel tablets designed to look, feel, and taste like treats, directly addressing the common challenge pet owners face when administering medications to reluctant animals.
Clinical validation comes from a study involving 31 dogs and 38 cats, which demonstrated that flavored Curablend Vet (搜索) tablets were voluntarily consumed by a large majority of animals, while unflavored tablets were frequently rejected. This data suggests the potential for significant improvements in medication adherence in veterinary applications.
Technology Platform and Capabilities
The Curablend Vet (搜索) system enables pharmacists to produce soft, flavored gel tablets with dose adjustments tailored to individual animals. The platform packages tablets individually for convenience and safety while utilizing the same automated, quality-controlled workflow that has been established in human medicine applications.
CurifyLabs (搜索)' 3D-printing technology, described as a first-of-its-kind compounding tool, is currently used in hospitals and pharmacies across the United States and Europe for preparing personalized medicines for humans. The platform replaces manual compounding steps with automated precision, allowing pharmacists to produce what the company characterizes as safer, more consistent doses in minutes.
Market Impact and Company Background
"Pet owners want medication time to be simple, not stressful," said Charlotta Topelius, CEO and Founder of CurifyLabs (搜索). "Curablend Vet (搜索) gives pharmacists a reliable way to make pet-friendly medicines that animals actually want to eat. We know how important pets are to families. And we're proud that Curablend Vet now brings the benefits of trusted 3D printed medicine to veterinary care."
Founded in 2021, CurifyLabs (搜索) has focused on transforming personalized medicine production through its 3D-printing-based Compounding System Solution (搜索). The company's technology combines specialized software, high-quality ingredients, and automated production to deliver customized treatments, with the veterinary application representing an expansion from its established human medicine platform.